MedTrace Logo

REDUCER Trial (TXA in Urethroplasty)

NCT07501884 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-30

No results posted yet for this study

Summary

This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.

Conditions

  • Urethral Stricture
  • Urethral Diseases

Interventions

DRUG

Tranexamic Acid

Tranexamic acid (TXA) will be administered perioperatively according to institutional protocol to reduce intraoperative and postoperative bleeding.

PROCEDURE

Urethroplasty

Surgical urethral reconstruction performed according to standard institutional techniques.

Sponsors & Collaborators

  • Amjad Alwaal, MD, MSc, FRCSC, FACS

    lead OTHER

Principal Investigators

  • Amjad Alwaal, MD, MSc, FACS · Rutgers University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-12-31
Completion
2027-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07501884 on ClinicalTrials.gov